[N:1]([CH:4]1[C:10](=[O:11])[N:9]([CH2:12][CH:13]2[CH2:15][CH2:14]2)[C:8]2[CH:16]=[CH:17][CH:18]=[CH:19][C:7]=2[N:6]([CH2:20][CH:21]2[CH2:23][CH2:22]2)[C:5]1=[O:24])=[N+]=[N-].N1C2C=CC=CC=2NCCC1>>[NH2:1][CH:4]1[C:10](=[O:11])[N:9]([CH2:12][CH:13]2[CH2:15][CH2:14]2)[C:8]2[CH:16]=[CH:17][CH:18]=[CH:19][C:7]=2[N:6]([CH2:20][CH:21]2[CH2:22][CH2:23]2)[C:5]1=[O:24]Following General Procedure 8-L using the product from Step B, 3-amino-2,4-dioxo-1,5-bis-cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine was prepared as a white solid. Purification was by flash chromatography eluting with CH2Cl2/MeOH (98:2 gradient to 95:5, with 5% NH3 in the MeOH) followed by recrystallization from warm CH2Cl2/hexanes (1:1) to −23° C.